Nurix Therapeutics’ (NRIX) Buy Rating Reaffirmed at Needham & Company LLC

Nurix Therapeutics (NASDAQ:NRIX)‘s stock had its “buy” rating restated by Needham & Company LLC in a report released on Tuesday, Benzinga reports. They presently have a $34.00 price objective on the stock. Needham & Company LLC’s price target points to a potential upside of 53.64% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Robert W. Baird increased their price target on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Mizuho upped their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Royal Bank Of Canada increased their target price on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Finally, Stifel Nicolaus lifted their price target on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Nurix Therapeutics Price Performance

Shares of NRIX traded down $0.03 during mid-day trading on Tuesday, reaching $22.13. The company’s stock had a trading volume of 4,680,804 shares, compared to its average volume of 1,491,495. Nurix Therapeutics has a 12-month low of $9.14 and a 12-month high of $28.23. The stock has a market cap of $2.30 billion, a PE ratio of -6.41 and a beta of 1.82. The company’s 50 day moving average is $25.22 and its 200 day moving average is $20.96.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share for the quarter, topping the consensus estimate of ($0.60) by $5.33. The firm had revenue of $673.06 million during the quarter, compared to analysts’ expectations of $24.35 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. As a group, sell-side analysts anticipate that Nurix Therapeutics will post -2.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Hans van Houte sold 4,761 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total value of $115,977.96. Following the completion of the sale, the chief financial officer owned 40,166 shares in the company, valued at $978,443.76. This represents a 10.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00. Following the completion of the sale, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. This trade represents a 3.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,372 shares of company stock worth $518,463 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NRIX. GAMMA Investing LLC grew its holdings in shares of Nurix Therapeutics by 95.4% during the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after buying an additional 620 shares during the last quarter. Farther Finance Advisors LLC increased its position in Nurix Therapeutics by 755.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,014 shares of the company’s stock valued at $95,000 after acquiring an additional 3,545 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Nurix Therapeutics in the 2nd quarter valued at about $33,000. Nykredit A S acquired a new position in Nurix Therapeutics in the 2nd quarter valued at about $32,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Nurix Therapeutics during the 2nd quarter valued at approximately $341,000.

Trending Headlines about Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix reported third-quarter 2026 EPS of $4.73, far above the consensus estimate of a $0.56–$0.60 loss, while revenue of $673.1 million substantially exceeded expectations of approximately $24 million. Nurix Therapeutics Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial, which is comparing bexobrutideg with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. This advances a key clinical program toward a potential approval opportunity. Nurix Therapeutics Third-Quarter Results and Corporate Update
• Positive Sentiment: RBC Capital Markets said Nurix’s enterprise value remains underappreciated, implying that the firm sees additional value in the company’s pipeline and outlook. Robert W. Baird raised its price target to $36 and maintained an outperform rating, while Needham reaffirmed its buy rating with a $34 target.
• Positive Sentiment: Truist maintained a buy rating and set a $33 price target, despite trimming its prior target from $34.
• Neutral Sentiment: The reported quarter included a very large revenue and EPS beat, but Nurix continues to post deeply negative profitability metrics. Investors may therefore be assessing how much of the quarter’s performance is recurring versus milestone-related or otherwise nonrecurring.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.